Lithium is the most effective mood-stabilizing drug in the therapy of bipolar affective disorder (BP). It is thought to exert its effect via the phosphatidylinositol signalling system. Myo-inositol monophosphatase 2 (IMPA2) codes for an enzyme in this system that is inhibited by lithium. It is located on 18p11.2, a region implicated as a BP susceptibility locus. We examined eight single-nucleotide polymorphisms (SNPs) identified within this gene for association with BP, using 237 parents-offspring trios and in 174 cases and 170 controls. No SNP showed association with BP. When good responders to lithium treatment were compared with the poor responders, some statistically significant differences emerged for two SNPs; however, the sample became too small to draw definitive conclusions. We cannot find support for the involvement of variation in IMPA2 in susceptibility to bipolar disorder, but the role of this and other genes from the phosphoinositol signalling pathway in predicting response to lithium treatment merits further investigation.
INTRODUCTION
Bipolar affective disorder (BP) is a complex genetic disorder with a lifetime prevalence of B1%. Family, twin and adoption studies have shown a major genetic contribution, with a heritability of 0.59 and recurrence risk in first-degree relatives of B10%. 1 The pathophysiology of the disorder is not yet known and so far the only insight has come from the mechanisms of actions of drugs used in its treatment. Lithium is an effective antimanic and prophylactic drug in the treatment of bipolar disorder. 2 Its mode of action is still not firmly established, but an effect on signal transduction pathways has been suggested. [3] [4] [5] According to the inositol depletion hypothesis, 6, 7 lithium works by blocking inositol phosphatases within excessively stimulated neurons. This results in lower levels of myo-inositol and decreases the concentration of phosphatidylinositol, which reduce cellular responses to neurotransmitters. Previous studies on INPP1, a gene encoding a dephosphorylating lithium-blockable enzyme, the inositol polyphosphate 1-phosphatase, have reported negative results from case-control and family-based association studies. 8, 9 Myo-inositol monophosphatase 2 (IMPA2) codes for a second human myo-inositol monophosphatase. The gene has been mapped to chromosome 18p11.2 10 and its structure has been characterized. 11, 12 The gene is a potential biochemical target for the action of lithium. 13 Linkage studies 14, 15 have suggested the presence of a susceptibility locus for bipolar disorder on chromosome 18p11.2. The gene has been screened for polymorphisms and tested for association with BP 11, 12 and schizophrenia. 16 Yoshikawa et al 12 described only three polymorphisms: 97À15G4A, 159T4C and 226C4T (His76Tyr), and tested their frequencies in 96 BP individuals and 59 unrelated persons from CEPH families. These single-nucleotide polymorphisms (SNPs) were reported as rare and differences did not reach statistical significance; however, the study was clearly underpowered to detect a more modest effect. Sjoholt et al 11 screened the gene in 23 individuals affected with BP and identified six previously unreported polymorphisms (230 þ 141G4A, 382À44G4A, 443G4A, 599 þ 75 delT, 599 þ 97G4A, 599 þ 99G4A), as well as 97À15G4A and 159T4C reported in Yoshikawa et al 12 (throughout the present paper we use the nomenclature used by Sjoholt et al, 11 so that for example, 58G4A, described by Yoshikawa et al 16 becomes À185G4A, etc). Yoshikawa et al 16 found seven other SNPs and tested À185G4A, 97À15G4A and 558C4T (the last one is now in the public databases as rs2075825) for association in 302 schizophrenics, 105 bipolar patients and 308 controls from Japan. They reported significant genotypic association (P-values between 0.031 and 0.0001) with schizophrenia, but not with bipolar disorder. Towards the end of our project, a family-based association study on 92 trios of Arab ethnicity was reported by Sjoholt et al, 17 who found that two SNPs in the IMPA2 promoter sequence (À461C4T and À207T4C) were preferentially transmitted to affected offspring (P-values of 0.006 and 0.002, respectively).
Given the likely complex genetic architecture of bipolar disorder, we felt that the above studies were underpowered to detect an allele or alleles conferring susceptibility to bipolar disorder. Moreover, we hypothesized that polymorphisms in IMPA2 might be even more important in influencing response to lithium treatment, rather than susceptibility to illness per se. A proportion of our patients recruited for genetic association studies had clearly shown a good response to lithium, while some had experienced no benefit at all. This gave us the opportunity to test this second hypothesis.
RESULTS
We first typed four SNPs in 30 BP trios in order to examine the allele frequencies and linkage disequilibrium (LD) between them (Table 1) . These were 97À15G4A, 443G4A(R148Q), 490 þ 13À14insA and 558C4T ( Figure 1 ). We found the T allele of 558C4T to be rare in our samples: only one parent in the first 30 trios was heterozygous, giving a frequency of 0.8% (Table 1 ). This contrasted with the original report on patients from Japan, where its frequency was 12%. The 490 þ 13À14insA was also very rare (three heterozygous parents, or a frequency of 2.4%). Such differences between European and Asian populations are well known (eg The International HapMap Consortium 18 ), so this result was not too surprising. This made these two SNPs unsuitable for LD mapping and we did not genotype them further. The A allele of 443G4A(R148Q) was also very rare. However, since this is a potentially functional variant, we typed it in the full sample of trios. It was present in o2% in the two populations studied and was transmitted six times and not transmitted nine times from heterozygous parents. The frequency of the minor allele A of 97À15G4A was only 13.5%. It was clear that the four SNPs that we chose initially were too rare and unsuitable to perform LD mapping of the gene. Therefore, we chose three further SNPs: 599 þ 97G4A and 599 þ 99G4A had been reported by Sjoholt et al, 11 and rs3786282 was selected from the public Figure 1 ). All three SNPs appeared to have minor allele frequencies B30% and we could be confident that they were going to be informative in our populations. Towards the end of the project, we became aware of a new paper 17 that described data on four common polymorphisms identified in the promoter of IMPA2. Two of these showed preferential transmission in 92 Palestinian Arab trios affected with BP. They were in almost complete LD with each other, so we genotyped only one of them: À461C4T.
The four additional common SNPs were genotyped in all our samples ( Table 1 ). The allele frequencies in the Bulgarian and UK parents were very similar (the highest difference between the two populations was just 2.2%). The LD pattern between these SNPs, as measured by D 0 and r 2 , also appeared very similar in these two populations ( Table 2 ). All four SNPs had frequencies of the minor alleles of 20-30%, but they captured different information, as indicated by the very low levels of r 2 ( Table 2 ). There was no preferential transmission from heterozygous parents for any of these SNPs, and no difference in the allele frequencies between cases and controls. These results provide no support for the possibility that variation in IMPA2 plays an important role in susceptibility to BP, although this study cannot exclude such a role.
We then investigated whether these variants influence the therapeutic response to lithium. We restricted the analysis to the four common SNPs: À461C4T, 599 þ 97G4A, 599 þ 99G4A and rs3786282, as we had too few observations to analyse the rarer polymorphisms. We analysed only UK patients from the trio and case samples, where we had identified 42 good responders and 35 poor responders. We compared the allele frequency of good vs poor responders. Although this difference reached 9% for rs3786282, none of the comparisons reached nominal levels of statistical significance, reflecting the small sample size ( Table 3) . The transmission disequilibrium test (TDT) for rs3786282 among the 19 good responders in the trios was T/NT ¼ 11/1 (P ¼ 0.004), with the minor allele C being overtransmitted, while the 24 poor responders showed a 10/10 transmission ratio. The minor allele A of 599 þ 97G4A was also statistically overtransmitted among the good responders, T/NT ¼ 11/3, P ¼ 0.033. Table 1 are not included because there were only four observations of the rare alleles, which would make the LD estimates highly misleading. The results in the table are from the Bulgarian sample, but they are nearly identical in the UK population (97-15G/A was not genotyped in the UK sample). Figure 1 The exon-intron structure of IMPA2 and the positions of the markers discussed in the present paper. 1 Found by Yoshikawa et al. Found by Sjoholt et al. 11 3 Selected from SNPs databases (eg http://genome.ucsc.edu/). * Genotyped by us (these SNPs are drawn below the line).
IMPA2, bipolar disorder and response to lithium DISCUSSION We have investigated the hypothesis that variation in IMPA2 increases susceptibility to BP, or confers a differential response to lithium treatment. As pointed out in the Introduction, this gene is both a positional and functional candidate for this disorder. We performed an association study using a matched sample of cases and controls, as well as a family-based design with the TDT, which is robust to population stratification. The sample of 237 trios genotyped in this study is among the larger collections of BP trios reported in the psychiatric literature.
Results from this study do not support the hypothesis of an association between the tested polymorphisms and BP. There were weak trends for preferential transmission in the UK trios (Table 1) ; however, the results among the Bulgarian trios were either completely negative (599 þ 97G4A and 599 þ 99G4A) or were in the opposite direction (À461C4T and rs3786282). The results in the case-control sample from the UK were negative, and all three populations showed similar allele frequencies and LD structure (Tables 1 and 2) .
Previous studies on INPP1, another gene encoding a lithium-inhibited enzyme from a neural signalling pathway, did not provide convincing results for its involvement in the aetiology of BP. 8, 9 Two genes encoding human IMPases have been identified: IMPA1 and IMPA2. IMPA2 was proposed as a plausible candidate gene by Yoshikawa et al, 10 because of its location within a region of positive linkage findings to BP 14, 15 and the possible functional role of the inositol phospholipid signalling system. Yoshikawa et al 16 reported that the group of haplotypes containing either À185A, 97-15G or 558C have significantly higher frequencies in schizophrenics, but not in bipolar disorder patients from Japan. Our study cannot replicate or reject these results because the minor allele frequencies of these SNPs were very low in the two European populations (Table 1) . Sjoholt et al 17 recently reported preferential transmission of two promoter SNPs in a sample of 92 Palestinian Arab trios. The two SNPs were in nearly complete LD and had identical allele frequencies, so we genotyped only one of them: -461C4T. In the original paper, the C allele of that SNP was transmitted 50 times and not transmitted 26 times from heterozygous parents to affected offspring. In our sample of trios from Bulgaria and the UK, it was transmitted 77 times and not transmitted 72 times and in the UK case-control sample, its frequency was actually lower in cases than in controls. Our failure to replicate the previous result could be due to different factors. The power of our combined sample to detect an effect of a similar magnitude in the trio sample was 80% for a P-value of 0.001 and our sample was about 2.5 times larger; therefore, it appears unlikely that our failure to replicate was due to our study being underpowered. It could be that this SNP is not the functional variant, but might be capturing a signal from other polymorphisms that have different allele frequencies and different LD in the Arab population. Indeed, the frequency of the C allele was different in the two populations: 69% in the parents in the Arab sample, and 76.6 and 78% in the parents of the UK and Bulgarian trios. The level of LD in the IMPA2 gene is very low, as can be seen from Table 2 , and a low LD was reported in Sjoholt et al. 17 Indeed, the only strong marker-marker LD in our sample was between 599_97G4A and 599_99G4A, which are just 2 bp from each other, as well as for the very rare 443G4A. This indicates that if there are susceptibility SNPs in this gene, their signals might not be captured by the common SNPs investigated, or they might be captured in one population, but not in another one. Finally, the previous study might have generated a false-positive result.
The 443G4A polymorphism predicts an amino-acid change at codon 148. Although it is not located in a conserved protein region, it may have a functional consequence since a basic amino acid (Arg) is replaced by a polar amino acid (Gln). We did not observe preferential trasmission of the rare glutamine allele to affected children from their parents in a total of 237 trios; in fact, the trend was in the opposite direction (six transmissions vs nine nontransmissions).
The three common SNPs (599 þ 97G4A, 599 þ 99G4A and rs3786282) are intronic and there is no indication that they may cause any functional or splicing alteration. Nevertheless, given their relative high heterozygosity, they seemed to be suitable for LD and association analysis. They displayed similar allele frequencies of around 30% in the UK and Bulgarian populations but they were not capturing identical signals, as indicated by the low r 2 between them f denotes the frequency of the minor allele in the full set of subjects from the UK: both trios and cases, 42 responders and 35 nonresponders. The P-value in the fourth column refers to the significance of the allele frequency differences between them. T/NT stands for the transmission/nontransmission of the minor allele from heterozygous parents to lithium responders (N ¼ 19 trios) and nonresponders (N ¼ 24 trios). 'R' stands for 'responders'.
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A Dimitrova et al (both D 0 and r 2 values were extremely similar in the too populations). Their alleles were almost equally transmitted or not transmitted in the trio samples and had similar frequencies between cases and controls. These results argue against the involvement of IMPA2 in the aetiology of BP. However, as discussed above, the low D 0 values between these SNPs indicate extensive recombination rates within the gene and we cannot exclude the possibility that other polymorphisms within and around it confer susceptibility.
Lithium is an effective treatment of BP, but only a proportion of patients benefit. The drug inhibits the enzyme IMPA2, so we reasoned that part of its differential treatment effect in BP could be due to genetic variation in IMPA2. Owing to his special interest in lithium treatment, the senior author of this paper (GK) had personally interviewed all the patients from the UK and recorded details of their lithium treatment and course of illness. He had identified 42 good and 35 poor responders to lithium, and we tested whether these two groups differed on the allele frequencies on any of the four common SNPs examined in the study. As presented in the Results and Table 2 , the overall comparison did not reach significance for any of the SNPs tested, but the small sample size prevents us from drawing more definitive conclusions. The transmission ratios of 11/1 for rs3786282 and 11/3 for 599 þ 97G4A are intriguing but could easily be chance findings, especially as the overall differences between responders and nonresponders were not significant and the sample is so small. The two SNPs are intronic and have no known functional effect, so if this trend proves to be a real one, it might be caused by other polymorphisms that are in LD with them.
We find that a clear rating of treatment response in psychiatric disorders is complicated and requires long-term observation of patients, detailed interviews and good clinical records. Over half of the patients could not be rated confidently on their response to treatment, even when all the data were available and the patient had been ill for many years (see Methods). This study shows that treatment response could be of value in pharmacogenetic studies, but very large samples of patients, detailed clinical records and long-term observations are required in order to confidently test for genetic associations.
In conclusion, we cannot support an association between polymorphisms in IMPA2 and BP in the Bulgarian and British populations, but we cannot exclude their role in influencing the therapeutic efficacy of lithium. Large independent samples of well-ascertained patients would be required in order to confirm or refute our findings. The low LD within this gene indicates that a much denser marker coverage is needed in order to confidently exclude it as a susceptibility factor for manic depressive disorder.
METHODS

Clinical Samples
We tested 121 Bulgarian patients affected with BP and all their parents. The recruitment of these nuclear families was performed by a team of over 40 psychiatrists in Bulgaria who also recruited families with schizophrenic probands. 19 The psychiatrists attended training courses at the beginning of the sample collection. The probands were either in-or outpatients under the care of the recruiting psychiatrists. Each proband was interviewed with an abbreviated version of the Schedules for Clinical Assessment in Neuropsychiatry (SCAN). 20 Consensus best estimate diagnoses were made according to DSM-IV criteria 21 by two researchers (GK and IN). About 25% of the patients were selected for a second interview by GK or IN. Cases with unclear diagnoses were excluded from the study.
In the UK, we recruited 116 parent-offspring trios and 174 unrelated BP patients, who were matched for age and gender with 170 healthy blood donors. All patients were interviewed in person by GK, who used the same rating scales, and consensus best-estimate diagnosis was made by him and another researcher, based on the interview and hospital notes that were available in each case.
Local Ethical Committee approval for the conduction of molecular genetic association studies was obtained from all the Ethics Committees where patients were recruited. All patients, their parents and the controls were given information on the project, and they signed a consent form for taking part in genetic association studies.
Rating of the Response to Lithium
For response to lithium, we used the following criteria: a patient could be rated as a good responder if he/she had a clear reduction in the number and/or severity of episodes during a lithium prophylaxis for at least 3 years, or on two or more occasions the patient had suffered a relapse within 4 weeks of stopping lithium. The interpretation of the term 'clear reduction' did not mean a completely symptom-free period, so that one episode of illness during lithium treatment could still be rated as a good response, if that patient had had frequent episodes of illness prior to starting lithium. The criteria for poor response required a similar length of observation and no change, or a worsening, of the course of illness. Any rating could be made only if there had been at least three episodes of illness prior to lithium prophylaxis and the effect of lithium had been observed for at least 3 years. Many patients reported that lithium helped them, but if the above criteria were not met, the case was not rated. Similarly, if the patient could not be unambiguously assigned to one of the two groups, the case was not rated. All ratings were performed by GK, who had interviewed the UK patients in person and had asked specific questions about the duration of lithium treatment and the response to it. In the full sample from the UK (cases and trios), there were 42 good responders and 35 poor responders. This means that a confident estimate of the quality of the lithium response could be made in only 77 out of the 156 patients who had received lithium treatment for their illness (49%). The mean onset of illness (defined as the age when the illness caused impairment of functioning) among the poor responders was 23.5 years (SD ¼ 6.6) and lithium was started, on average, 5.3 years (SD ¼ 6.8) later. Among the good responders, these figures were 27.3 years (SD ¼ 10.0) IMPA2, bipolar disorder and response to lithium A Dimitrova et al and 7.5 years (SD ¼ 9.3). The vast majority of patients came from specialized lithium clinics where they received regular monitoring and their lithium levels were kept within the therapeutic range of 0.5-1.0 mmol/l. For obvious reasons, we did not rate patients who had shown poor compliance with lithium treatment over the years. The UK sample was collected during 1996-1997. There were 13 patients who were rated on their lithium response and who had remained under the care of the senior author of this paper (GK) in his Lithium clinic in Cardiff until now. This gave us the opportunity to assess the accuracy of the ratings after a 7-8 year follow-up on this subsample of patients. Among these 13 patients, four had been rated as poor and nine as good responders. One of the poor responders has since been in remission, but only after the addition of carbamazepine. Two of the good responders changed their lithium with carbamazepine. One remained in remission and the other one suffered two major manic relapses since. The rest of the patients have continued their lithium treatment and their status had not changed, in fact, the remaining seven good responders had not been hospitalized since. We therefore conclude that our strict selection criteria for rating the response to lithium were valid. Lithium was used much less frequently, or for shorter periods of time, in the Bulgarian patients, and most of them have not been interviewed in person by GK, so very few of them satisfied our criteria for lithium response. Therefore, our analysis was restricted to the UK patients only.
Genotyping
Genomic DNA was extracted from blood through phenolchloroform extraction. Four SNPs, 97À15G4A, 443G4A, 558C4T and 490 þ 13À14insA were genotyped by extension of fluorescently labelled primers. 19, 22 Standard PCR conditions were used to amplify DNA fragments containing the SNPs. This was followed by treatment with exonuclease I and alkaline phosphatase to inactivate primers and dNTPs (USBiological, Cleveland, OH, USA). Primer extension was performed in 10 ml volume with 2.5 ml PCR template, 0.04 mM of the appropriate ddNTP and the remaining three dNTPs, chosen so that the primer extends by a different number of nucleotides, depending on the SNP, 0.25 U Thermosequenase (Amersham, UK), 0.07 ml of fluorescently labelled primer (at 10 pmol/ ml) and buffer supplied by the manufacturer. Extension primers were designed so that their 3 0 -end anneals one or two bases short of the SNP to allow better separation between the peaks produced by the nonextended and the extended primers. Extension primes were designed with an in-house-developed programme (http://m034.pc.uwcm.ac.uk/FP_Primer.html). Primers were 5 0 labelled with a fluorescent dye (FAM, TET or HEX). An initial denaturation step at 951C for 3 min was followed by 50 cycles at 451C for 10 s and 951C for 10 s. Primer extension products were separated on 15% acrylamide gels using Long Ranger s gel solution (BMA, Rockland, USA) on ABI373 automated sequencers. Following electrophoresis, all fragments were sized relative to an internal size standard using ABI Genescan v3.1t software and the genotypes for each SNP defined using the ABI Genotyper v2.5t software. The internal size standard consisted of TAMRA-labelled nucleotides with a size of 13, 20, 35 and 43 bp.
During the course of this project, we switched our genotyping to the faster Amplifluort SNP Genotyping System 23, 24 and followed the recommendations of the manufacturer (Serologicals Corporation, Norcross, GA, USA). The method uses allele-specific amplification and universal energy-transfer-labelled primers. The products were resolved on an Analyst AD fluorescence reader (LJL Biosystems, Sunnyvale, CA, USA). Amplifluort was used to genotype 599 þ 97G4A, 599 þ 99G4A and rs3786282. The promoter polymorphism À461C4T could not be genotyped with the Amplifluort method, probably due to the high GC content of the region, so we used fluorescence polarization with the Acycloprime TM technology (Perkin-Elmer Life Sciences, USA).
Statistical Analysis
Preferential transmission of alleles from heterozygous parents to affected offspring was analysed by the TDT. 25 Comparison of allele frequencies between poor and good responders was made with w 2 statistics. Our combined set of 237 trios has a power of 80% to detect a significant result at the P ¼ 0.05 level for markers with a minor allele frequency of 0.3 (like the four common SNPs investigated in the present study), for an additive mode of transmission and a genotype relative risk of 1.5 or greater, as estimated with the formulas suggested by Camp. 26 Pairwise LD between the SNPs was estimated by calculating the Lewontin D 0 value 27 and the r 2 coefficient 28 in the two trio samples and is based on phase-certain haplotypes.
Choice of SNPs
In order to provide the most cost-effective coverage of the gene, we used SNPs reported in previous publications, supplemented with SNPs for the public databases. In a population from Japan, 16 558C4T and 97À15G4A have been reported as showing allelic association with schizophrenia, so we felt that they should be typed in our samples. Sjoholt et al 11 had found the 490 þ 13À14insA, 97À15G4A, 599 þ 97G4A, 599 þ 99G4A and 443G4A(Arg148Gln) to have allele frequencies ranging from 0.02 to 0.35 in European patients, which gave us confidence that these SNPs would be polymorphic in our samples. rs3786282 was chosen from public databases, as it was validated as being common. Finally, À461C4T was added at the end of the study, as it had shown a statistically significant result with BP in a recent publication. 17 Bulgaria was funded by the Janssen Research Foundation (Beerse, Belgium). The work of AD was funded by the Socrates/Erasmus European programme.
